CY1115246T1 - Τροποποιησεις toy rna, οι οποιες οδηγουν σε αυξημενη σταθεροτητα μεταγραφηματων και αποτελεσματικοτητα μεταφρασης - Google Patents

Τροποποιησεις toy rna, οι οποιες οδηγουν σε αυξημενη σταθεροτητα μεταγραφηματων και αποτελεσματικοτητα μεταφρασης

Info

Publication number
CY1115246T1
CY1115246T1 CY20141100498T CY141100498T CY1115246T1 CY 1115246 T1 CY1115246 T1 CY 1115246T1 CY 20141100498 T CY20141100498 T CY 20141100498T CY 141100498 T CY141100498 T CY 141100498T CY 1115246 T1 CY1115246 T1 CY 1115246T1
Authority
CY
Cyprus
Prior art keywords
transfer
toy
lead
stability
increased
Prior art date
Application number
CY20141100498T
Other languages
English (en)
Inventor
Ugur Sahin
Silke Holtkamp
Özlem Türeci
Sebastian Kreiter
Original Assignee
Biontech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Ag filed Critical Biontech Ag
Publication of CY1115246T1 publication Critical patent/CY1115246T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση αφορά τη σταθεροποίηση του RNA, ιδιαιτέρως του mRNA, και την αύξηση της μετάφρασης του mRNA. Η παρούσα εφεύρεση αφορά ιδιαιτέρως τρεις τροποποιήσεις του RNA, ιδιαιτέρως in vitro μεταγραμμένου RNA, οι οποίες οδηγούν σε αυξημένη σταθερότητα μεταγραφημάτων και αποτελεσματικότητα μετάφρασης.
CY20141100498T 2005-09-28 2014-07-02 Τροποποιησεις toy rna, οι οποιες οδηγουν σε αυξημενη σταθεροτητα μεταγραφηματων και αποτελεσματικοτητα μεταφρασης CY1115246T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005046490A DE102005046490A1 (de) 2005-09-28 2005-09-28 Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
EP10014763.6A EP2357230B1 (de) 2005-09-28 2006-09-28 Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen

Publications (1)

Publication Number Publication Date
CY1115246T1 true CY1115246T1 (el) 2017-01-04

Family

ID=37685276

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121100514T CY1113526T1 (el) 2005-09-28 2012-06-06 Τροποποιησεις του rνα, οι οποιες οδηγουν σε αυξημενη σταθεροτητα μεταγραφηματων και αποτελεσματικοτητα mεταφρασης
CY20141100498T CY1115246T1 (el) 2005-09-28 2014-07-02 Τροποποιησεις toy rna, οι οποιες οδηγουν σε αυξημενη σταθεροτητα μεταγραφηματων και αποτελεσματικοτητα μεταφρασης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20121100514T CY1113526T1 (el) 2005-09-28 2012-06-06 Τροποποιησεις του rνα, οι οποιες οδηγουν σε αυξημενη σταθεροτητα μεταγραφηματων και αποτελεσματικοτητα mεταφρασης

Country Status (18)

Country Link
US (4) US9476055B2 (el)
EP (2) EP2357230B1 (el)
JP (3) JP5435949B2 (el)
AT (1) ATE550427T1 (el)
AU (1) AU2006296702B2 (el)
CA (2) CA3023101C (el)
CY (2) CY1113526T1 (el)
DE (1) DE102005046490A1 (el)
DK (2) DK1934345T3 (el)
ES (2) ES2384113T3 (el)
HK (1) HK1155477A1 (el)
HR (2) HRP20120480T1 (el)
IN (1) IN2014CN02116A (el)
PL (2) PL2357230T3 (el)
PT (2) PT2357230E (el)
RS (2) RS52353B (el)
SI (2) SI1934345T1 (el)
WO (1) WO2007036366A2 (el)

Families Citing this family (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
RU2399667C1 (ru) * 2009-04-10 2010-09-20 Общество С Ограниченной Ответственностью "Лаборатория Клеточных Технологий" Способ получения плюрипотентных клеток
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
ES2770335T3 (es) 2010-07-06 2020-07-01 Glaxosmithkline Biologicals Sa Administración de ARN para desencadenar múltiples vías inmunológicas
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
BR112013000244A2 (pt) 2010-07-06 2016-05-17 Novartis Ag lipossomas com lipídeos apresentando pka vantajoso para administração de rna
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
AU2011295935B2 (en) 2010-08-31 2016-02-11 Glaxosmithkline Biologicals S.A. Pegylated liposomes for delivery of immunogen-encoding RNA
CN104531812A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
KR102266691B1 (ko) 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US10738355B2 (en) 2011-05-24 2020-08-11 Tron-Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Ggmbh Individualized vaccines for cancer
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
EP3348644B1 (en) 2012-02-15 2020-02-12 CureVac AG Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
EP3404103B1 (en) 2012-02-15 2021-03-24 CureVac AG Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
EP3348645B1 (en) 2012-02-15 2020-06-03 CureVac AG Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2868391A1 (en) 2012-04-02 2013-10-10 Stephane Bancel Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
US20140010861A1 (en) 2012-04-02 2014-01-09 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2885419A4 (en) 2012-08-14 2016-05-25 Moderna Therapeutics Inc ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
SG11201503593UA (en) 2012-11-13 2015-06-29 Biontech Ag Agents for treatment of claudin expressing cancer diseases
EP3766903A3 (en) 2012-11-13 2021-02-17 BioNTech SE Bispecific anti claudin xcd3 antibodies for treatment of claudin expressing cancer diseases
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
EP3417874A1 (en) 2012-11-28 2018-12-26 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
AU2013374345A1 (en) 2013-01-17 2015-08-06 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
PT3019619T (pt) 2013-07-11 2021-11-11 Modernatx Inc Composições que compreendem polinucleótidos sintéticos que codificam proteínas relacionadas com crispr e sgarn sintéticos e métodos de utilização
JP2016530294A (ja) 2013-09-03 2016-09-29 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． キメラポリヌクレオチド
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
EP3082760A1 (en) 2013-12-19 2016-10-26 Novartis AG LEPTIN mRNA COMPOSITIONS AND FORMULATIONS
PT3134131T (pt) 2014-04-23 2022-03-24 Modernatx Inc Vacinas de ácidos nucleicos
WO2016005004A1 (en) * 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
CA2955250A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2016057850A1 (en) 2014-10-09 2016-04-14 Seattle Children' S Hospital (Dba Seattle Children' S Research Institute) Long poly (a) plasmids and methods for introduction of long poly (a) sequences into the plasmid
DE202015009974U1 (de) * 2014-12-12 2022-02-17 Curevac Ag Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
DK4155409T3 (da) * 2015-08-10 2024-02-26 Curevac Mfg Gmbh Fremgangsmåde til at øge replikationen af et cirkulært dna-molekyle
JP6990176B2 (ja) 2015-10-05 2022-02-03 モデルナティエックス インコーポレイテッド メッセンジャーリボ核酸薬物の治療投与のための方法
WO2017059902A1 (en) * 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
DK3362461T3 (da) 2015-10-16 2022-05-09 Modernatx Inc Mrna-cap-analoger med modificeret phosphatbinding
US11866754B2 (en) 2015-10-16 2024-01-09 Modernatx, Inc. Trinucleotide mRNA cap analogs
AU2016340183A1 (en) * 2015-10-16 2018-04-19 Modernatx, Inc. mRNA cap analogs and methods of mRNA capping
HRP20220525T1 (hr) 2015-12-23 2022-05-27 Modernatx, Inc. Postupci uporabe polinukleotida koji kodiraju ligand ox40
EP3400023A1 (en) 2016-01-10 2018-11-14 ModernaTX, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
EP3442590A2 (en) 2016-04-13 2019-02-20 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
PT3445850T (pt) 2016-04-22 2021-12-06 BioNTech SE Métodos para proporcionar arn de cadeia simples
EP3445392A1 (en) 2016-04-22 2019-02-27 CureVac AG Rna encoding a tumor antigen
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
JP7114485B2 (ja) 2016-05-18 2022-08-08 モデルナティエックス インコーポレイテッド ファブリー病の治療のためのα－ガラクトシダーゼＡをコードするポリヌクレオチド
JP7194594B2 (ja) 2016-05-18 2022-12-22 モデルナティエックス インコーポレイテッド 免疫調節ポリペプチドをコードするｍＲＮＡの組み合わせ及びその使用
WO2017201348A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
WO2017201332A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency
LT3458083T (lt) 2016-05-18 2023-02-10 Modernatx, Inc. Polinukleotidai, koduojantys interleukiną-12 (il12), ir jų naudojimas
WO2017201342A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
US10993918B2 (en) 2016-05-18 2021-05-04 Modernatx, Inc. Polynucleotides encoding citrin for the treatment of Citrullinemia type 2
CA3024624A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
WO2018013525A1 (en) 2016-07-11 2018-01-18 Translate Bio Ma, Inc. Nucleic acid conjugates and uses thereof
WO2018081788A1 (en) 2016-10-31 2018-05-03 Cornell University Methods of enhancing translation ability and stability of rna molecules, treatments, and kits
US11485972B2 (en) 2017-05-18 2022-11-01 Modernatx, Inc. Modified messenger RNA comprising functional RNA elements
EP3625246A1 (en) 2017-05-18 2020-03-25 ModernaTX, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
US20200268666A1 (en) 2017-06-14 2020-08-27 Modernatx, Inc. Polynucleotides encoding coagulation factor viii
WO2018231990A2 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
WO2019036670A2 (en) 2017-08-18 2019-02-21 Modernatx, Inc. EFFECTIVE MRNA VACCINES
US11859215B2 (en) 2017-11-22 2024-01-02 Modernatx, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
JP7423521B2 (ja) 2017-11-22 2024-01-29 モダーナティエックス・インコーポレイテッド フェニルケトン尿症の治療用のフェニルアラニンヒドロキシラーゼをコードするポリヌクレオチド
MA50802A (fr) 2017-11-22 2020-09-30 Modernatx Inc Polynucléotides codant pour des sous-unités alpha et bêta de propionyl-coa carboxylase pour le traitement de l'acidémie propionique
EP3724208A4 (en) 2017-12-15 2021-09-01 Flagship Pioneering Innovations VI, LLC COMPOSITIONS WITH CIRCULAR POLYRIBONUCLEOTIDES AND USES THEREOF
EP3735270A1 (en) 2018-01-05 2020-11-11 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
BR112020026125A8 (pt) 2018-03-15 2022-10-18 Biontech Rna Pharmaceuticals Gmbh Compostos oligonucleotídeos superiores ou 5'-cap- trinucleotídeo e seus usos na estabilização de rna, expressão de proteínas e em terapia
EP3773745A1 (en) 2018-04-11 2021-02-17 ModernaTX, Inc. Messenger rna comprising functional rna elements
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
WO2020047201A1 (en) 2018-09-02 2020-03-05 Modernatx, Inc. Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
WO2020056155A2 (en) 2018-09-13 2020-03-19 Modernatx, Inc. Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
CA3112208A1 (en) 2018-09-13 2020-03-19 Modernatx, Inc. Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease
AU2019338535A1 (en) 2018-09-14 2021-04-15 Modernatx, Inc. Methods and compositions for treating cancer using mRNA therapeutics
JP2022500444A (ja) 2018-09-14 2022-01-04 モダーナティエックス・インコーポレイテッドModernaTX, Inc. クリグラー−ナジャー症候群の治療のためのウリジン二リン酸グリコシルトランスフェラーゼ１ファミリー、ポリペプチドａ１をコードするポリヌクレオチド
WO2020069169A1 (en) 2018-09-27 2020-04-02 Modernatx, Inc. Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
MX2021007241A (es) 2018-12-19 2021-09-23 Versameb Ag Acido ribonucleico (arn) que codifica para una proteina.
CA3124837A1 (en) 2019-01-14 2020-07-23 Genentech, Inc. Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
AU2020231349A1 (en) 2019-03-01 2021-09-23 Flagship Pioneering Innovations Vi, Llc Compositions, methods, and kits for delivery of polyribonucleotides
JP2022522768A (ja) 2019-03-01 2022-04-20 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー ポリリボヌクレオチド及びその化粧用の使用
US20230086537A1 (en) 2019-05-07 2023-03-23 Modernatx, Inc. Differentially expressed immune cell micrornas for regulation of protein expression
JP2022531461A (ja) 2019-05-07 2022-07-06 モデルナティエックス インコーポレイテッド 免疫細胞活性を破壊するポリヌクレオチド及びその使用方法
TWI777160B (zh) * 2019-05-08 2022-09-11 美商百歐恩泰美國公司 T細胞製備組合物及方法
CN114375190A (zh) 2019-05-08 2022-04-19 阿斯利康(瑞典)有限公司 用于皮肤和伤口的组合物及其使用方法
EP3986480A1 (en) 2019-06-24 2022-04-27 ModernaTX, Inc. Messenger rna comprising functional rna elements and uses thereof
EP3987027A1 (en) 2019-06-24 2022-04-27 ModernaTX, Inc. Endonuclease-resistant messenger rna and uses thereof
WO2021008708A1 (en) 2019-07-18 2021-01-21 Biontech Rna Pharmaceuticals Gmbh Method for determining at least one parameter of a sample composition comprising nucleic acid, such as rna, and optionally particles
CA3158013A1 (en) 2019-10-15 2021-04-22 Modernatx, Inc. Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease
CN115175698A (zh) 2020-01-28 2022-10-11 摩登纳特斯有限公司 冠状病毒rna疫苗
TW202142689A (zh) 2020-01-29 2021-11-16 美商旗艦先鋒創新有限責任公司 用於轉譯之組合物及其使用方法
CN115397459A (zh) 2020-01-31 2022-11-25 基因泰克公司 用pd-1轴结合拮抗剂和rna疫苗诱导新表位特异性t细胞的方法
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
CA3170150A1 (en) 2020-02-07 2021-08-12 Modernatx, Inc. Sars-cov-2 mrna domain vaccines
CA3167611A1 (en) 2020-02-13 2021-08-19 Etienne Simon-Loriere Nucleic acid vaccine against the sars-cov-2 coronavirus
CN115811986A (zh) 2020-04-22 2023-03-17 生物技术欧洲股份公司 冠状病毒疫苗
WO2021222304A1 (en) 2020-04-27 2021-11-04 Modernatx, Inc. Sars-cov-2 rna vaccines
JP2023526059A (ja) 2020-05-14 2023-06-20 モダーナティエックス・インコーポレイテッド ｍＲＮＡ治療薬及びエフェクター分子を含むＬＮＰ組成物
WO2021159130A2 (en) 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use
US20230235298A1 (en) 2020-06-01 2023-07-27 Modernatx, Inc. Phenylalanine hydroxylase variants and uses thereof
WO2021247535A1 (en) 2020-06-01 2021-12-09 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
CN116194151A (zh) 2020-06-23 2023-05-30 摩登纳特斯有限公司 包含具有延长的半衰期的mRNA治疗剂的LNP组合物
CN111893128A (zh) * 2020-06-24 2020-11-06 苏州市泽悦生物技术有限公司 利用原核转录系统制备重组真核mRNA的方法及其应用
BR112023000827A2 (pt) 2020-07-17 2023-02-07 Genentech Inc Métodos, vacina, métodos para fabricar uma vacina, para tratar um indivíduo e para fabricar um tratamento para um indivíduo, composição farmacêutica, peptídeo imunogênico, sequência de ácido nucleico, sistema e produto de programa de computador
JP2023540134A (ja) 2020-09-08 2023-09-21 ジェネンテック， インコーポレイテッド 蠕動式ポンプおよび減衰装置を使用して薬学的組成物を生産するためのシステムおよび方法
US20230355743A1 (en) 2020-09-25 2023-11-09 Modernatx, Inc. Multi-proline-substituted coronavirus spike protein vaccines
EP4203997A1 (en) 2020-10-26 2023-07-05 Pécsi Tudományegyetem Vaccine platform
AU2021377895A1 (en) 2020-11-13 2023-06-15 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2022101471A1 (en) 2020-11-16 2022-05-19 BioNTech SE Pharmaceutical compositions comprising lipid nanoparticles and mrna, and methods for preparing and storing the same
TW202237148A (zh) 2020-11-16 2022-10-01 德商拜恩迪克公司 包含rna之lnp組合物以及製備、儲存及使用彼之方法
WO2022218503A1 (en) 2021-04-12 2022-10-20 BioNTech SE Lnp compositions comprising rna and methods for preparing, storing and using the same
WO2022106860A1 (en) 2020-11-20 2022-05-27 Pécsi Tudományegyetem Recombinant peptides for use in therapy
JP2023553343A (ja) 2020-11-25 2023-12-21 アカゲラ・メディスンズ，インコーポレイテッド 核酸を送達するための脂質ナノ粒子および関連する使用方法
JP2024502210A (ja) 2020-12-22 2024-01-17 キュアバック エスイー ＳＡＲＳ－ＣｏＶ－２バリアントに対するＲＮＡワクチン
US20230000970A1 (en) 2021-01-11 2023-01-05 Modernatx, Inc. Seasonal rna influenza virus vaccines
JP2024503699A (ja) 2021-01-15 2024-01-26 モデルナティエックス インコーポレイテッド バリアント株ベースのコロナウイルスワクチン
US20240100151A1 (en) 2021-01-15 2024-03-28 Moderna TX, Inc. Variant strain-based coronavirus vaccines
WO2022162027A2 (en) 2021-01-27 2022-08-04 Curevac Ag Method of reducing the immunostimulatory properties of in vitro transcribed rna
WO2022174079A1 (en) 2021-02-12 2022-08-18 Modernatx, Inc. Lnp compositions comprising payloads for in vivo therapy
EP4308156A1 (en) 2021-03-15 2024-01-24 ModernaTX, Inc. Therapeutic use of sars-cov-2 mrna domain vaccines
WO2022204369A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
US20240207374A1 (en) 2021-03-24 2024-06-27 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
WO2022204380A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
US20240207444A1 (en) 2021-03-24 2024-06-27 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
EP4314260A1 (en) 2021-03-24 2024-02-07 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
AU2022249357A1 (en) 2021-04-01 2023-10-12 Modernatx, Inc. Methods for identification and ratio determination of rna species in multivalent rna compositions
WO2022218891A2 (en) 2021-04-12 2022-10-20 BioNTech SE Rna compositions comprising a buffer substance and methods for preparing, storing and using the same
WO2022221335A1 (en) 2021-04-13 2022-10-20 Modernatx, Inc. Respiratory virus combination vaccines
AU2022258463A1 (en) 2021-04-14 2023-11-23 Modernatx, Inc. Influenza-coronavirus combination vaccines
KR20240006575A (ko) 2021-04-26 2024-01-15 앵스띠뛰 파스퇴르 SARS-CoV-2에 대한 사람 중화 모노클로날 항체 및 이의 용도
AU2022270658A1 (en) 2021-05-04 2023-11-16 BioNTech SE Technologies for early detection of variants of interest
WO2022246020A1 (en) 2021-05-19 2022-11-24 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
WO2022245888A1 (en) 2021-05-19 2022-11-24 Modernatx, Inc. Seasonal flu rna vaccines and methods of use
EP4355882A2 (en) 2021-06-15 2024-04-24 Modernatx, Inc. Engineered polynucleotides for cell-type or microenvironment-specific expression
WO2022266389A1 (en) 2021-06-17 2022-12-22 Modernatx, Inc. Alternative rna purification strategies
WO2022271776A1 (en) 2021-06-22 2022-12-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
WO2023287751A1 (en) 2021-07-12 2023-01-19 Modernatx, Inc. Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
WO2023009499A1 (en) 2021-07-27 2023-02-02 Modernatx, Inc. Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease type 1a (gsd1a)
WO2023006920A1 (en) 2021-07-29 2023-02-02 BioNTech SE Compositions and methods for treatment of melanoma
TW202321446A (zh) 2021-08-13 2023-06-01 美商現代公司 多管柱層析ｍＲＮＡ純化
CN115216483B (zh) * 2021-08-30 2024-01-23 中国科学院遗传与发育生物学研究所 poly(A)尾巴非A修饰在促进mRNA翻译中的应用
WO2023030635A1 (en) 2021-09-02 2023-03-09 BioNTech SE Potency assay for therapeutic potential of coding nucleic acid
WO2023036960A1 (en) 2021-09-10 2023-03-16 BioNTech SE Lipid-based rna formulations suitable for therapy
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
WO2023056044A1 (en) 2021-10-01 2023-04-06 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
WO2023064469A1 (en) 2021-10-13 2023-04-20 Modernatx, Inc. Compositions of mrna-encoded il15 fusion proteins and methods of use thereof
WO2023067126A1 (en) 2021-10-22 2023-04-27 BioNTech SE Oligosaccharide compounds and complexes
EP4285933A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide complexes and uses
EP4285932A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide complexes and uses
EP4169579A1 (en) 2021-10-22 2023-04-26 BioNTech SE Disulfide oligosaccharide compounds and complexes
EP4169578A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide compounds and complexes
EP4186528A1 (en) 2021-11-30 2023-05-31 BioNTech SE Oligosaccharide complexes and uses
EP4286394A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide compounds and complexes
CA3235867A1 (en) 2021-10-22 2023-04-27 Munir MOSAHEB Mrna vaccine composition
WO2023067123A1 (en) 2021-10-22 2023-04-27 BioNTech SE Oligosaccharide complexes and uses
EP4286003A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide compounds and complexes
WO2023067121A1 (en) 2021-10-22 2023-04-27 BioNTech SE Oligosaccharide compounds and complexes
EP4169580A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide compounds and complexes
WO2023067125A1 (en) 2021-10-22 2023-04-27 BioNTech SE Oligosaccharide complexes and uses
WO2023067124A1 (en) 2021-10-22 2023-04-27 BioNTech SE Disulfide oligosaccharide compounds and complexes
EP4286004A1 (en) 2022-05-30 2023-12-06 BioNTech SE Disulfide oligosaccharide compounds and complexes
EP4169534A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide complexes and uses
CA3234578A1 (en) 2021-10-22 2023-04-27 Advait Vijay Badkar Compositions for administration of different doses of rna
WO2023073190A1 (en) 2021-10-28 2023-05-04 BioNTech SE Rna constructs and uses thereof
WO2023077170A1 (en) 2021-11-01 2023-05-04 Modernatx, Inc. Polynucleotides encoding integrin beta-6 and methods of use thereof
WO2023076658A1 (en) 2021-11-01 2023-05-04 Modernatx, Inc. Mass spectrometry of mrna
WO2023081311A1 (en) 2021-11-05 2023-05-11 Modernatx, Inc. Methods of purifying dna for gene synthesis
WO2023083434A1 (en) 2021-11-09 2023-05-19 BioNTech SE Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection
WO2023092069A1 (en) 2021-11-18 2023-05-25 Modernatx, Inc. Sars-cov-2 mrna domain vaccines and methods of use
WO2023096858A1 (en) 2021-11-23 2023-06-01 Senda Biosciences, Inc. A bacteria-derived lipid composition and use thereof
WO2023107999A2 (en) 2021-12-08 2023-06-15 Modernatx, Inc. Herpes simplex virus mrna vaccines
WO2023122080A1 (en) 2021-12-20 2023-06-29 Senda Biosciences, Inc. Compositions comprising mrna and lipid reconstructed plant messenger packs
WO2023126053A1 (en) 2021-12-28 2023-07-06 BioNTech SE Lipid-based formulations for administration of rna
WO2023132885A1 (en) 2022-01-04 2023-07-13 Modernatx, Inc. Methods of purifying dna for gene synthesis
WO2023137149A1 (en) 2022-01-14 2023-07-20 Modernatx, Inc. In vitro transcription dna purification and recycling
WO2023141501A2 (en) * 2022-01-19 2023-07-27 Virginia Tech Intellectual Properties, Inc. Nudix overexpressing engineered plants and uses thereof
WO2023148276A1 (en) 2022-02-02 2023-08-10 BioNTech SE Agents and methods for targeted delivery to cells
WO2023148277A1 (en) 2022-02-02 2023-08-10 BioNTech SE Agents and methods for targeted delivery of nucleic acids to cells
WO2023150256A1 (en) 2022-02-03 2023-08-10 Modernatx, Inc. Continuous precipitation for mrna purification
TW202345864A (zh) 2022-02-18 2023-12-01 美商現代公司 編碼檢查點癌症疫苗之ｍＲＮＡ及其用途
WO2023165681A1 (en) 2022-03-01 2023-09-07 BioNTech SE Rna lipid nanoparticles (lnps) comprising a polyoxazoline and/or polyoxazine polymer
WO2023183909A2 (en) 2022-03-25 2023-09-28 Modernatx, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
WO2023193892A1 (en) 2022-04-05 2023-10-12 BioNTech SE Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same
WO2023196399A1 (en) 2022-04-06 2023-10-12 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria
WO2023196914A1 (en) 2022-04-08 2023-10-12 Modernatx, Inc. Influenza nucleic acid compositions and uses thereof
WO2023201296A1 (en) 2022-04-15 2023-10-19 Modernatx, Inc. Ribosomal engagement potency assay
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023230481A1 (en) 2022-05-24 2023-11-30 Modernatx, Inc. Orthopoxvirus vaccines
WO2023232747A1 (en) 2022-05-30 2023-12-07 BioNTech SE Complexes for delivery of nucleic acids
WO2023237726A1 (en) 2022-06-10 2023-12-14 Pantarhei Oncology B.V. An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2024010993A1 (en) 2022-07-06 2024-01-11 Modernatx, Inc. Primer design for cell-free dna production
WO2024015890A1 (en) 2022-07-13 2024-01-18 Modernatx, Inc. Norovirus mrna vaccines
WO2024028325A1 (en) 2022-08-01 2024-02-08 BioNTech SE Nucleic acid compositions comprising amphiphilic oligo ethylene glycol (oeg)-conjugated compounds and methods of using such compounds and compositions
WO2024028445A1 (en) 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
WO2024027910A1 (en) 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
WO2024050483A1 (en) 2022-08-31 2024-03-07 Modernatx, Inc. Variant strain-based coronavirus vaccines and uses thereof
WO2024063788A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024068674A1 (en) 2022-09-26 2024-04-04 BioNTech SE Nucleic acid complexes and uses thereof
WO2024084462A1 (en) 2022-10-21 2024-04-25 BioNTech SE Nucleic acid complexes and uses thereof
WO2024097874A1 (en) 2022-11-03 2024-05-10 Modernatx, Inc. Chemical stability of mrna
WO2024102434A1 (en) 2022-11-10 2024-05-16 Senda Biosciences, Inc. Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
WO2024107754A1 (en) 2022-11-15 2024-05-23 Genentech, Inc. Selection of diverse candidate peptides for peptide therapeutics
WO2024130158A1 (en) 2022-12-16 2024-06-20 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5824497A (en) * 1995-02-10 1998-10-20 Mcmaster University High efficiency translation of mRNA molecules
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
JP4108126B2 (ja) 1996-04-26 2008-06-25 リュクスウニヴェルシテート テ レイデン Ｔ細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン
ES2305157T3 (es) 1996-09-13 2008-11-01 Lipoxen Technologies Limited Liposomas.
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US6074645A (en) 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
EP1021549A2 (en) 1997-09-19 2000-07-26 Sequitur, Inc. SENSE mRNA THERAPY
CA2309557A1 (en) 1997-11-06 1999-05-20 Roche Diagnostics Gmbh Tumor-specific antigens, methods for their production and their use for immunization and diagnosis
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
CA2345440A1 (en) 1998-10-05 2000-04-13 Charles A. Nicolette Genes differentially expressed in cancer cells to design cancer vaccines
DE60041183D1 (de) 1999-05-06 2009-02-05 Univ Wake Forest Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen
EP1261704B1 (en) 1999-11-30 2009-07-01 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
EP1242108B1 (en) 1999-12-28 2007-07-11 Pharmexa Inc. Optimized minigenes and peptides encoded thereby
WO2001093902A2 (en) 2000-06-07 2001-12-13 Biosynexus Incorporated Immunostimulatory rna/dna hybrid molecules
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
WO2002072844A1 (en) * 2001-03-09 2002-09-19 Gene Stream Pty Ltd Novel expression vectors
GB0111015D0 (en) * 2001-05-04 2001-06-27 Norsk Hydro As Genetic material
ATE464317T1 (de) 2001-06-05 2010-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt für die gentherapie
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AUPS054702A0 (en) 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
US7399753B2 (en) * 2002-02-25 2008-07-15 Virxsys Corporation Trans-splicing mediated photodynamic therapy
EP1361277A1 (en) * 2002-04-30 2003-11-12 Centre National De La Recherche Scientifique (Cnrs) Optimization of transgene expression in mammalian cells
JP2005529187A (ja) 2002-06-13 2005-09-29 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 同種抗原の特定方法、ならびに癌治療および移植へのその使用
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DK2286794T3 (en) 2003-10-15 2016-07-25 Syncore Biotechnology Co Ltd USE OF CATIONIC LIPOSOMES, WHICH INCLUDES paclitaxel
US20070202119A1 (en) 2003-10-24 2007-08-30 Ashdown Martin L Method Of Therapy
US7303881B2 (en) 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102004057303A1 (de) 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
MX2007008010A (es) 2004-12-29 2007-09-07 Mannkind Corp Metodos para desviar celulas cd4+ en la induccion de una inmuno respuesta.
KR101339628B1 (ko) 2005-05-09 2013-12-09 메다렉스, 인코포레이티드 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
RS63964B1 (sr) 2005-08-23 2023-03-31 Univ Pennsylvania Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu
DE102005041616B4 (de) 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
AU2007220042A1 (en) 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
AU2007342338A1 (en) 2006-09-20 2008-07-17 The Johns Hopkins University Combinatorial therapy of cancer and infectious diseases with anti-B7-H1 antibodies
DE102006060824B4 (de) 2006-12-21 2011-06-01 Johannes-Gutenberg-Universität Mainz Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten
MX351975B (es) 2006-12-27 2017-11-06 Emory Univ Star Composiciones y metodos para el tratamiento de infecciones y tumores.
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US8140270B2 (en) 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
PL2170959T3 (pl) 2007-06-18 2014-03-31 Merck Sharp & Dohme Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
ES2436540T3 (es) 2008-03-24 2014-01-02 4Sc Discovery Gmbh Nuevas imidazoquinolinas sustituidas
RU2530555C2 (ru) 2008-04-17 2014-10-10 ПиДиЭс БАЙОТЕКНОЛОДЖИ КОРПОРЭЙШН Стимуляция иммунного ответа энантиомерами катионных липидов
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
CA2769670C (en) 2009-07-31 2018-10-02 Ethris Gmbh Rna with a combination of unmodified and modified nucleotides for protein expression
KR102447139B1 (ko) 2010-05-14 2022-09-23 더 제너럴 하스피톨 코포레이션 종양 특이적 신생항원을 확인하는 조성물 및 방법
CN104531812A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
DE102011102734A1 (de) 2011-05-20 2012-11-22 WMF Württembergische Metallwarenfabrik Aktiengesellschaft Vorrichtung zum Aufschäumen von Milch, Getränkebereiter mit dieser Vorrichtung und Verfahren zum Aufschäumen von Milch
EP2771349B1 (en) 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
WO2013106496A1 (en) 2012-01-10 2013-07-18 modeRNA Therapeutics Methods and compositions for targeting agents into and across the blood-brain barrier
US9321808B2 (en) 2012-02-20 2016-04-26 Biontech Ag Homo- and heterodimeric SMAC mimetic compounds as apoptosis inducers
US20130255281A1 (en) 2012-03-29 2013-10-03 General Electric Company System and method for cooling electrical components
US20140010861A1 (en) 2012-04-02 2014-01-09 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US20130274129A1 (en) * 2012-04-04 2013-10-17 Geneart Ag Tal-effector assembly platform, customized services, kits and assays
MX364370B (es) 2012-07-12 2019-04-24 Persimmune Inc Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas.
US20150307542A1 (en) 2012-10-03 2015-10-29 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
CA2890110C (en) 2012-11-01 2023-05-02 Factor Bioscience Inc. Methods and products for expressing proteins in cells
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
EP2964234A4 (en) 2013-03-09 2016-12-07 Moderna Therapeutics Inc NON-TRANSLATED HETEROLOGOUS REGIONS FOR MRNA
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US20160032316A1 (en) 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
EP2983804A4 (en) 2013-03-15 2017-03-01 Moderna Therapeutics, Inc. Ion exchange purification of mrna
WO2014144711A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
WO2014144039A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Characterization of mrna molecules
EP2971165A4 (en) 2013-03-15 2016-11-23 Moderna Therapeutics Inc DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
EP4279610A3 (en) 2013-03-15 2024-01-03 ModernaTX, Inc. Ribonucleic acid purification
CN105377292A (zh) 2013-04-07 2016-03-02 博德研究所 用于个性化瘤形成疫苗的组合物和方法
WO2015014375A1 (en) 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
JP2016530294A (ja) 2013-09-03 2016-09-29 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． キメラポリヌクレオチド
WO2015038892A1 (en) 2013-09-13 2015-03-19 Moderna Therapeutics, Inc. Polynucleotide compositions containing amino acids
EP3049065A1 (en) 2013-09-26 2016-08-03 BioNTech AG Particles comprising a shell with rna
WO2015051173A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc Polynucleotide molecules and uses thereof
US10385088B2 (en) 2013-10-02 2019-08-20 Modernatx, Inc. Polynucleotide molecules and uses thereof
WO2015058780A1 (en) 2013-10-25 2015-04-30 Biontech Ag Method and kit for determining whether a subject shows an immune response
WO2015085318A2 (en) 2013-12-06 2015-06-11 Moderna Therapeutics, Inc. Targeted adaptive vaccines
EP3053585A1 (en) 2013-12-13 2016-08-10 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
AU2014381849A1 (en) 2014-02-05 2016-08-25 Biontech Ag A cannula, an injection or infusion device and methods of using the cannula or the injection or infusion device
PT3134131T (pt) 2014-04-23 2022-03-24 Modernatx Inc Vacinas de ácidos nucleicos
WO2015172843A1 (en) 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Methods and kits for the diagnosis of cancer
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
DE202015009974U1 (de) 2014-12-12 2022-02-17 Curevac Ag Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
BR112017009835A2 (pt) 2014-12-30 2017-12-26 Curevac Ag moléculas de ácido nucleico artificiais
WO2016155809A1 (en) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell

Also Published As

Publication number Publication date
CA3023101C (en) 2022-09-06
EP1934345B9 (de) 2012-07-18
DK2357230T3 (da) 2014-06-02
HK1155477A1 (en) 2012-05-18
PL2357230T3 (pl) 2014-08-29
ES2384113T9 (es) 2012-10-16
CA3023101A1 (en) 2007-04-05
DK1934345T3 (da) 2012-07-23
PL1934345T3 (pl) 2012-09-28
AU2006296702A1 (en) 2007-04-05
SI2357230T1 (sl) 2014-07-31
EP2357230B1 (de) 2014-05-07
ATE550427T1 (de) 2012-04-15
JP2009509516A (ja) 2009-03-12
JP2016027811A (ja) 2016-02-25
RS52353B (en) 2012-12-31
WO2007036366A3 (de) 2007-06-21
JP2012235786A (ja) 2012-12-06
JP5435949B2 (ja) 2014-03-05
CA2621444A1 (en) 2007-04-05
SI1934345T1 (sl) 2012-07-31
JP6058928B2 (ja) 2017-01-11
HRP20140561T1 (hr) 2014-07-18
US20100129877A1 (en) 2010-05-27
EP2357230A1 (de) 2011-08-17
PT2357230E (pt) 2014-07-15
DE102005046490A1 (de) 2007-03-29
AU2006296702B2 (en) 2011-12-08
WO2007036366A2 (de) 2007-04-05
RS53351B (en) 2014-10-31
WO2007036366A8 (de) 2012-05-31
US20190062762A1 (en) 2019-02-28
US20230193296A1 (en) 2023-06-22
EP1934345B1 (de) 2012-03-21
EP1934345A2 (de) 2008-06-25
PT1934345E (pt) 2012-06-21
ES2384113T3 (es) 2012-06-29
ES2467678T3 (es) 2014-06-12
US20170009244A1 (en) 2017-01-12
CA2621444C (en) 2019-11-12
US10106800B2 (en) 2018-10-23
US9476055B2 (en) 2016-10-25
HRP20120480T1 (hr) 2012-07-31
IN2014CN02116A (el) 2015-05-29
CY1113526T1 (el) 2016-06-22

Similar Documents

Publication Publication Date Title
CY1115246T1 (el) Τροποποιησεις toy rna, οι οποιες οδηγουν σε αυξημενη σταθεροτητα μεταγραφηματων και αποτελεσματικοτητα μεταφρασης
CY1122347T1 (el) 3' utr αλληλουχιες για τη σταθεροποιηση toy rna
CY1122861T1 (el) Φαρμακευτικες συνθεσεις της αμορφης μορφης ν-[2,4-δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3-καρβοξαμιδιου
CY1119979T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν τοξοειδη α και β toy clostridium difficile
CY1113819T1 (el) Σκευασματα για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1118710T1 (el) Συνθεσεις για την θεραπεια της πολλαπλης σκληρυνσης
EA200702643A1 (ru) Антитела, связывающие tweak
CY1108344T1 (el) Φορεις εκφρασης που περιεχουν τον mcmv ie2 υποκινητη
EA200701918A1 (ru) Белок липокалин
DE602005015994D1 (de) siRNA-VERMITTELTES GEN-SILENCING VON ALPHA-SYNUKLEIN
CY1115147T1 (el) Εξουδετερωτικα αντισωματα που εχουν ειδικοτητα για ανθρωπινη il-17
CY1114504T1 (el) Συνθεσεις τιγεκυκλινης και μεθοδοι παρασκευης
NO20070263L (no) Immunostimulerende oligonukleotidmultimerer
CY1108447T1 (el) Προφαρμακο αμιδιου της γεμσιταβινης, οι συνθεσεις και η χρηση τους
DK1713912T3 (da) Modificerede Korte Interfererende RNA (Modificerede siRNA)
CY1117328T1 (el) Διαδικασια για την παρασκευη πολυσιαλικου οξεος υψηλης καθαρiοτητας
EA200901109A1 (ru) Применение n-фениламидинов в качестве гербицидов
AU2009236219A8 (en) Silencing of CSN5 gene expression using interfering RNA
CY1115786T1 (el) Μεσο φυλαξης για κυτταρα
DK2057153T3 (da) (3-aryl-piperazin-1-yl)-derivater af 6,7 dialkoxyquinazolin, 6,7- dialkoxyphtalazin og 6,7-dialkoxyisoquinolin
ATE512228T1 (de) Induzierbare expressionssysteme
DE502006005053D1 (de) Spritzbare akustikmassen
DE602006016879D1 (de) Sprachsynthetisator mit multiplen Lauten
CY1120368T1 (el) Αλληλουχια ειδικης διασπασης μμρ-14
CY1110891T1 (el) Παραγωγα 6-ετεροαρυλπυριδοϊνδολονης, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη αγωγη